|
|
|
|
AstraZeneca - Discovery Alliances
AstraZeneca has a world-leading R&D organization and one of the best pipelines in the industry. We have over 10,000 people dedicated to the discovery and development of innovative new medicines that meet the needs of patients worldwide.
Our approach
Annual investment of over $2.7 billion to improve the quality and efficiency of our discovery process and ensure a flow of high potential candidates for development as new products.
Vigorous research programme focused on seven areas of medical need.
Globally managed research organisation with 10,000 staff at nine sites in the UK, US, Sweden, Canada and India.
Major focus on advanced enabling science and technology methods, such as informatics and genetics.
Commitment to improving productivity in drug discovery and development.
Continued emphasis on the formation of strategic research partnerships with academic and commercial partners to complement in-house skills.
Platform Technologies
Through its own resources and strategic collaborations with universities and biotechnology companies, AstraZeneca has broad access to advanced technologies in genomics, bioinformatics, chemical libraries, high throughput screening and product delivery systems.
Therapeutic focus includes:
Oncology
Signal transduction inhibitors
Antiangiogenic agents
Antiproliferative agents
Apoptosis inducers
Targeted cytotoxics
Current oncology Pipeline includes
Oestrogen receptor down regulator
Signal transduction inhibitor
Thymidilate synthase inhibitors
Vascular targeting agent
Angiogenesis inhibitors
FTI
|
|
|
|
NEW SERVICE !
|
PRODUCT AWARD
|
|
PERSPECTIVES
|
|
OFFICIAL PARTNERS
|
|
|
